Intelligent Bio Solutions Updates Share Capital Structure
TipRanks (Fri, 11-Sep 5:26 PM ET)
Intelligent Bio Solutions to Host Virtual Fireside Chat on September 24th at 4:30 p.m. ET
Globe Newswire (Thu, 10-Sep 8:30 AM ET)
Globe Newswire (Wed, 9-Sep 8:30 AM ET)
Globe Newswire (Tue, 1-Sep 8:31 AM ET)
Globe Newswire (Tue, 1-Sep 8:30 AM ET)
Globe Newswire (Wed, 19-Aug 8:30 AM ET)
Intelligent Bio Solutions Strengthens Quality Management Credentials with ISO Recertification
Globe Newswire (Mon, 17-Aug 8:30 AM ET)
Globe Newswire (Tue, 11-Aug 8:30 AM ET)
Intelligent Bio Solutions Completes Usability Study Supporting FDA 510(k) Submission
Globe Newswire (Wed, 5-Aug 8:30 AM ET)
Globe Newswire (Mon, 3-Aug 8:30 AM ET)
Intelligent Bio Solutions Inc is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. Its current active product is the Intelligent Fingerprinting Platform, consisting of a proprietary portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader. Its flagship product, the Intelligent Fingerprinting Drug Screening System, is a two-part system of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse, including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Company operates in APAC, the UK, the Americas, and the rest of the world, with maximum revenue from the United Kingdom.
Intelligent Bio Solutions trades on the NASDAQ stock market under the symbol INBS.
As of September 16, 2026, INBS stock price declined to $2.01 with 9,716 million shares trading.
INBS has a beta of 1.80, meaning it tends to be more sensitive to market movements. INBS has a correlation of 0.02 to the broad based SPY ETF.
INBS has a market cap of $6.09 million. This is considered a Sub-Micro Cap stock.
Last quarter Intelligent Bio Solutions reported $1 million in Revenue and -$.90 earnings per share. This fell short of revenue expectation by $-74,000 and exceeded earnings estimates by $.68.
In the last 3 years, INBS traded as high as $186.38 and as low as $1.52.
The top ETF exchange traded funds that INBS belongs to (by Net Assets): VXF.
INBS has underperformed the market in the last year with a price return of -88.3% while the SPY ETF gained +16.1%. INBS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -13.7% and -17.3%, respectively, while the SPY returned +0.9% and -0.3%, respectively.
INBS support price is $1.89 and resistance is $2.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INBS shares will trade within this expected range on the day.